Navigation Links
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Date:5/13/2009

Fixed-dose combination offers a convenient option that may help patients reduce steps to reach their blood pressure goals while decreasing patient pill burden(1)

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Daiichi Sankyo, Inc. today announced that the United States Food and Drug Administration (FDA) has approved the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial or 'first-line' therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure (BP) goals. The FDA approval of AZOR for first-line use reinforces current U.S. guidelines to prescribe combination drugs as initial therapy for patients likely to need more than one drug. According to the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), more than two-thirds of hypertensive individuals are not controlled on one drug and require two or more medications selected from different drug classes to achieve their BP goal.(2)

"The approval of AZOR as a first-line therapy gives doctors an important treatment option that may help the many patients who require multiple medications avoid several treatment steps to achieve their blood pressure goals," said Dr. Keith C. Ferdinand, M.D., chief science officer, Association of Black Cardiologists and clinical professor, Emory School of Medicine. "Fixed-dose combinations like AZOR provide patients with a more convenient option than separate monotherapies, which may help simplify the treatment regimen and decrease overall pill burden."

High blood pressure can cause permanent changes to blood vessels and the heart that may create serious problems elsewhere in the body.(3) Hypertension is one of the most prevalent conditions in the United States, affecting approximately one in three American adults (about 73 million people age 20 and older) and approximately one billion people worldwide.(4),(5) I
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. CSC Receives SAP Pinnacle Award for Global IT Outsourcing
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. AMDL Inc.s JJB Plant Receives Production Approval From Chinese State Food and Drug Administration (SFDA)
4. Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL
5. UIC receives $1M HUD grant to study green healthy housing
6. PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward
7. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
8. Isolagen Receives Bridge Financing to Allow it to Seek Debtor-in-Possession Financing in Connection With a Possible Filing Under Chapter 11 of the United States Bankruptcy Code
9. Bertram Receives Organizational Innovation Award at AONE Conference -- Award Sponsor B. E. Smith Also Announces Funding for Three Seed Grants
10. AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R)
11. WuXi AppTec Receives 2009 Lilly Global Supplier Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... in brain cells may hold clues for Parkinson,s treatment, researchers ... they,ve discovered collections of brain cells that may play a ... in things like playing the piano and driving a car. ... found the cells in the prefrontal cortex and striatum parts ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... Neurologists at the University at Buffalo are beginning ... on the cause of multiple sclerosis (MS). The researchers ... result from narrowing of the primary veins outside the ... CCSVI. CCSVI is a complex vascular condition ...
... Sexual trauma also associated with women,s urinary tract symptoms, ... -- Psychiatric disorders and sexual trauma in women increase ... as incontinence and overactive bladder, a new study finds. ... -- the Urogenital Distress Inventory-6 and Incontinence Impact Questionnaire-7 ...
... antidepressants for depression never get relief. Why? Because ... to treat it aim at the wrong target, according to ... The medications are like arrows shot at the outer rings ... A study from the laboratory of long-time depression researcher Eva ...
... researchers find , FRIDAY, Oct. 23 (HealthDay News) -- A ... seven-day course in reducing pain after children have their tonsils ... in the October issue of the Archives of Otolaryngology ... tonsillectomy can make children reluctant to eat and drink, leading ...
Cached Medicine News:Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 3Health News:Buffalo neurologists investigate possible new underlying cause of MS 4Health News:Bladder Problems May Often Be Related to Mental Health 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3Health News:After Tonsillectomy, Short-Term Antibiotics Effective: Study 2
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 15 Theranostics Health (TH) today,announced that ... Registration from the,Federal Government. This, along with ... Maryland Department of Health & Mental Hygiene, ... testing in the,disciplines/specialties of Immunology/protein microarray and,Pathology/histopathology., ...
... With Deep Vein, Thrombosis; $10 Million National ... Drug- Device Technique Can Prevent Post-Thrombotic Syndrome, FAIRFAX, ... trial of a catheter-based treatment for deep vein thrombosis,-- ... with clot,removal devices to prevent post-thrombotic syndrome in patients ...
Cached Medicine Technology:Theranostics Health Receives Green Light to Perform Clinical Testing 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 3Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 4
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
... The PulseOx 5500TM is the ... blood oxygen saturation and heart rate ... The PulseOx 5500TM uses SPO Medicals ... device which is more usable for ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: